The Prognostic Role and Utility of Highly Sensitive Minimal Residual Disease Assay in Multiple Myeloma: Is There Really a Difference?

被引：0
|
作者：
Fonseca, Rodrigo [1 ]
Wiedmeier, Julia E. [1 ]
Arribas, Mariano [1 ]
Fonseca, Rafael [1 ]
机构：
[1] Mayo Clin, Phoenix, AZ USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷
关键词：
MM; multiple myeloma; minimal; residual disease; next-generation sequencing;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MM-361
引用
收藏
页码：S420 / S420
页数：1
相关论文
共 50 条
  • [41] The Prognostic Significance of Minimal Residual Disease in Multiple Myeloma in the Molecular Genetic Groups Msmart 3.0
    Garifullin, Andrey
    Voloshin, Sergei
    Linnikov, Sergey
    Martynkevich, Irina
    Kuvshinov, Alexey
    Kuzyaeva, Anastasiya
    Chubukina, Zhanna
    Shuvaev, Vasily
    Kleina, Elizaveta
    Bakai, Marina
    Hmidt, Alexander S.
    BLOOD, 2020, 136
  • [42] Dynamic monitoring of minimal residual disease reveals its superior prognostic significance in multiple myeloma
    Jin, Fengyan
    Landgren, C. Ola
    Dai, Yun
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E47 - E48
  • [43] Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications
    Charalampous, Charalampos
    Kourelis, Taxiarchis
    FRONTIERS IN ONCOLOGY, 2022, 11
  • [44] Comparison of EasyM, a clonotypic mass spectrometry assay, and EuroFlow minimal residual disease assessment in multiple myeloma
    Zhao, Jessie
    Khong, Tiffany
    Gorniak, Malgorzata
    Khaled, Abir
    Mcdonald, Zac
    Reynolds, John
    Mithraprabhu, Sridurga
    Bingham, Nicholas
    Lim, Suehli
    Wong, Daniel
    Johnston, Anna
    Motorna, Olga
    Murphy, Nicholas
    Quach, Hang
    Yang, Liqiang
    Spencer, Andrew
    HAEMATOLOGICA, 2025, 110 (03) : 764 - 767
  • [45] Evaluation of Easym, a Clonotypic Mass Spectrometry Assay, and Euroflow Minimal Residual Disease Assessment in Multiple Myeloma
    Zhao, Jessie
    Khong, Tiffany T.
    Gorniak, Malgorzata
    Khaled, Abir
    McDonald, Zac
    Reynolds, John
    Wong, Daniel
    Bingham, Nicholas
    Johnston, Anna M.
    Motorna, Olga
    Murphy, Nicholas E.
    Quach, Hang
    Yang, Liqiang
    Spencer, Andrew
    BLOOD, 2023, 142
  • [46] Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter?
    Kothari, Shalin
    Hillengass, Jens
    McCarthy, Philip L.
    Holstein, Sarah A.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2019, 14 (01) : 39 - 46
  • [47] Multiple myeloma patient perceptions of minimal residual disease testing
    Hydren, Jay
    Martinez, Jorge Arturo Hurtado
    Quiroz, Felipe Flores
    Perez, Patricia Alejandra Flores
    Espinoza, Andrea Isabel Robles
    Vicencio, Andrea Jimena Cuevas
    Flores, Marilu Najera
    Hernandez, Eduardo Franco
    Aldana, Ana Sahagun Sanchez
    Sweeney, Nathan
    Ahlstrom, Jennifer
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S74 - S74
  • [48] Minimal residual disease in multiple myeloma: Benefits of flow cytometry
    Galtseva, I. V.
    Davydova, Y. O.
    Kapranov, N. M.
    Julhakyan, H. L.
    Mendeleeva, L. P.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2018, 40 (01) : 12 - 20
  • [49] Minimal residual disease in multiple myeloma: bringing the bench to the bedside
    Mailankody, Sham
    Korde, Neha
    Lesokhin, Alexander M.
    Lendvai, Nikoletta
    Hassoun, Hani
    Stetler-Stevenson, Maryalice
    Landgren, Ola
    NATURE REVIEWS CLINICAL ONCOLOGY, 2015, 12 (05) : 286 - U139
  • [50] Minimal residual disease in multiple myeloma: bringing the bench to the bedside
    Sham Mailankody
    Neha Korde
    Alexander M. Lesokhin
    Nikoletta Lendvai
    Hani Hassoun
    Maryalice Stetler-Stevenson
    Ola Landgren
    Nature Reviews Clinical Oncology, 2015, 12 : 286 - 295
12345